Guhan Pharmaceutical Group Co

Guhan Pharmaceutical Group Co Current Liabilities

The Current Liabilities of Guhan Pharmaceutical Group Co (000590.SZ) as of Oct 30, 2026 is 67.77 M CNY. In the previous year, Current Liabilities was 283.90 M CNY — a change of -76.13% (lower).

Current Liabilities

67.77 MCNY

YoY

-76.13%

Last updated:

Current Liabilities of Guhan Pharmaceutical Group Co is 2025 67.77 M CNY. Current Liabilities of Guhan Pharmaceutical Group Co was 2024 283.90 M CNY. It decreases by -76.13% lower compared to the previous year.

The Guhan Pharmaceutical Group Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
154.51 M CNY
Jan 1, 2019
170.29 M CNY
Jan 1, 2020
162.41 M CNY
Jan 1, 2021
174.24 M CNY
Jan 1, 2022
318.20 M CNY
Jan 1, 2023
305.45 M CNY
Jan 1, 2024
283.90 M CNY
Jan 1, 2025
67.77 M CNY
The Guhan Pharmaceutical Group Co Current Liabilities history
YEARCurrent LiabilitiesYoY
67.77 MCNY-76.13%
283.90 MCNY-7.05%
305.45 MCNY-4.01%
318.20 MCNY+82.62%
174.24 MCNY+7.28%
162.41 MCNY-4.63%
170.29 MCNY+10.21%
154.51 MCNY-14.68%
181.09 MCNY+26.20%
143.50 MCNY-51.21%
294.09 MCNY+22.51%
240.06 MCNY-9.28%
264.62 MCNY+52.29%
173.76 MCNY-29.83%
247.62 MCNY-22.55%
319.71 MCNY+8.74%
294.00 MCNY+4.91%
280.25 MCNY+18.64%
236.22 MCNY-17.93%
287.81 MCNY-28.94%
405.04 MCNY-1.44%
410.94 MCNY-2.90%
423.23 MCNY-7.14%
455.79 MCNY+2.41%
445.07 MCNY+57.39%
282.79 MCNY-5.79%
300.19 MCNY+149.83%
120.16 MCNY+28.77%
93.31 MCNY+211.04%
30.00 MCNY-46.52%
56.10 MCNY—
0.00CNY—
0.00CNY—
0.00CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Guhan Pharmaceutical Group Co Stock analysis

What does Guhan Pharmaceutical Group Co do? Tus-Pharmaceutical Group Co., Ltd. generates revenue through the research and development, production, and sales of Chinese patent medicine and western medicine preparations. The company offers Chinese healthcare products, cold treatment medicines, and anti hyperlipemia medicines, alongside western medicine products such as clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection. Domestic markets are the primary sales channel for all products. The firm's revenue streams are derived from the sale of these pharmaceutical products to domestic customers. The company focuses on Chinese patent medicine, including healthcare products, cold treatment remedies, and anti hyperlipemia treatments. Western medicine preparations like clindamycin phosphate for injection, lomefloxacin hydrochloride for injection, and levofloxacin lactate for injection form a significant part of its product portfolio. These products are distributed exclusively within China, targeting domestic consumers and healthcare providers. Tus-Pharmaceutical Group Co., Ltd. serves domestic markets with its range of Chinese and western medicines. The company's product lines include Chinese healthcare products, cold treatment medicines, anti hyperlipemia medicines, and specific western medicine injections. Sales are conducted within China, with no mention of international distribution. The firm's revenue is generated through the direct sale of these pharmaceutical products to domestic buyers. Guhan Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guhan Pharmaceutical Group Co stock

Current Liabilities of Guhan Pharmaceutical Group Co is 67.77 M CNY in 2025.

Current Liabilities of Guhan Pharmaceutical Group Co changed from 283.90 M CNY to 67.77 M CNY, representing a -76.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Guhan Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Guhan Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Guhan Pharmaceutical Group Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Guhan Pharmaceutical Group Co